Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: An analysis of volume and zonal distribution of tumour foci

BJU International

Volumn 105, Issue 10, 2010, Pages 1386-1391

  Davis, John W ^a   Kim, Jeri ^b   Ward, John F ^a   Wang, Xuemai ^b   Nakanishi, Hiro ^a   Babaian, R Joseph ^a   Troncoso, Patricia ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Active surveillance; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SAMPLE SIZE; TUMOR VOLUME;

ADULT; AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 77951708084     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08964.x     Document Type: Article

References (21)

1. Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: update 2007. J Urol 2007 177 : 2106 2131 (Pubitemid 46726449)
2. Ochiai A, Trpkov K, Yilmaz A, Donnelly B, Babaian RJ. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 2007 177 : 907 910
3. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986 11 : 60 3
4. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990 66 : 1225 1233
5. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 1990 14 : 240 247
6. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993 71 : 933 938
7. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 1995 154 : 1808 1812
8. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000 89 : 1800 1809
9. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Path 2003 27 : 1291 1301
10. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched White men. Cancer 2006 107 : 75 82
11. Jack GS, Cookson MS, Coffey CS et al. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. J Urol 2002 168 : 519 524
12. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008 179 : 1804 1809
13. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with no palpable prostate cancer. J Urol 2001 166 : 104 110
14. Griffin CR, Yu X, Loeb S, Desireddi VN, Han M, Graif T, Catalona WF. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol 2007 178 : 860 863
15. Chun FK, Suardi N, Capitanio U et al. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol 2009 55 : 617 628
16. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005 23 : 8165 8169
17. Nakanishi H, Wang X, Ochiai A et al. A nomogram for predicting low-volume /low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 2007 110 : 2441 2447
18. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HG, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007 177 : 107 112
19. Raaijmakers R, deVries SH, Blijenberg BG et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol 2007 52 : 1358 1364
20. Van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localized prostate cancer managed by active surveillance. Eur Urol 2008 54 : 1297 1305
21. Carter HB, Kettermann A, Warlick C et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins Experience. J Urol 2007 178 : 2359 2365